Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, outlines recent advances in the field of graft-versus-host disease (GvHD). To start with, the introduction of post-transplant cyclophosphamide (PTCy) has greatly improved the prevention of GvHD. Moreover, while in the frontline setting, both acute and chronic GvHD are still mostly treated with high-dose steroids, several drugs have recently been approved for the treatment of refractory GvHD. These include ibrutinib, ruxolitinib and belumosudil, and together with advances in microbiota modulation and fecal microbiota transplantation (FMT), these tools will greatly improve the outcomes of patients with GvHD. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.

свернуть